BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

750 related articles for article (PubMed ID: 27580057)

  • 1. Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.
    Fan LC; Teng HW; Shiau CW; Tai WT; Hung MH; Yang SH; Jiang JK; Chen KF
    Oncotarget; 2016 Sep; 7(39):64136-64147. PubMed ID: 27580057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SHP-1 is a target of regorafenib in colorectal cancer.
    Fan LC; Teng HW; Shiau CW; Lin H; Hung MH; Chen YL; Huang JW; Tai WT; Yu HC; Chen KF
    Oncotarget; 2014 Aug; 5(15):6243-51. PubMed ID: 25071018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer.
    Fan LC; Teng HW; Shiau CW; Tai WT; Hung MH; Yang SH; Jiang JK; Chen KF
    Neoplasia; 2015 Sep; 17(9):687-696. PubMed ID: 26476076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.
    Ji Q; Liu X; Han Z; Zhou L; Sui H; Yan L; Jiang H; Ren J; Cai J; Li Q
    BMC Cancer; 2015 Mar; 15():97. PubMed ID: 25884904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma.
    Fan LC; Shiau CW; Tai WT; Hung MH; Chu PY; Hsieh FS; Lin H; Yu HC; Chen KF
    Oncogene; 2015 Oct; 34(41):5252-63. PubMed ID: 25619838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
    Tai WT; Chu PY; Shiau CW; Chen YL; Li YS; Hung MH; Chen LJ; Chen PL; Su JC; Lin PY; Yu HC; Chen KF
    Clin Cancer Res; 2014 Nov; 20(22):5768-76. PubMed ID: 25248379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic trioxide attenuates STAT-3 activity and epithelial-mesenchymal transition through induction of SHP-1 in gastric cancer cells.
    Kim SH; Yoo HS; Joo MK; Kim T; Park JJ; Lee BJ; Chun HJ; Lee SW; Bak YT
    BMC Cancer; 2018 Feb; 18(1):150. PubMed ID: 29409467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis.
    Su JC; Mar AC; Wu SH; Tai WT; Chu PY; Wu CY; Tseng LM; Lee TC; Chen KF; Liu CY; Chiu HC; Shiau CW
    Sci Rep; 2016 Jul; 6():28888. PubMed ID: 27364975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDGF-D promotes cell growth, aggressiveness, angiogenesis and EMT transformation of colorectal cancer by activation of Notch1/Twist1 pathway.
    Chen J; Yuan W; Wu L; Tang Q; Xia Q; Ji J; Liu Z; Ma Z; Zhou Z; Cheng Y; Shu X
    Oncotarget; 2017 Feb; 8(6):9961-9973. PubMed ID: 28035069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BIX02189 inhibits TGF-β1-induced lung cancer cell metastasis by directly targeting TGF-β type I receptor.
    Park SJ; Choi YS; Lee S; Lee YJ; Hong S; Han S; Kim BC
    Cancer Lett; 2016 Oct; 381(2):314-22. PubMed ID: 27543359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regorafenib inhibits migration, invasion, and vasculogenic mimicry of hepatocellular carcinoma via targeting ID1-mediated EMT.
    Zhang N; Zhang S; Wu W; Lu W; Jiang M; Zheng N; Huang J; Wang L; Liu H; Zheng M; Wang J
    Mol Carcinog; 2021 Feb; 60(2):151-163. PubMed ID: 33428809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ZnAs@SiO
    Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
    Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
    [No Abstract]   [Full Text] [Related]  

  • 13. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
    Liu YC; Tsai JJ; Weng YS; Hsu FT
    Biomed Pharmacother; 2020 Aug; 128():110319. PubMed ID: 32502841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ginsenoside Rb2 inhibits epithelial-mesenchymal transition of colorectal cancer cells by suppressing TGF-β/Smad signaling.
    Dai G; Sun B; Gong T; Pan Z; Meng Q; Ju W
    Phytomedicine; 2019 Mar; 56():126-135. PubMed ID: 30668333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
    Wang CY; Chao TT; Tai WT; Chang FY; Su WP; Chen YL; Chen PT; Weng CY; Yuan A; Shiau CW; Yu CJ; Chen KF
    J Thorac Oncol; 2014 Apr; 9(4):488-96. PubMed ID: 24736071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
    Su JC; Chiang HC; Tseng PH; Tai WT; Hsu CY; Li YS; Huang JW; Ko CH; Lin MW; Chu PY; Liu CY; Chen KF; Shiau CW
    Carcinogenesis; 2014 Dec; 35(12):2807-14. PubMed ID: 25322871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allicin Inhibits Proliferation and Invasion in Vitro and in Vivo via SHP-1-Mediated STAT3 Signaling in Cholangiocarcinoma.
    Chen H; Zhu B; Zhao L; Liu Y; Zhao F; Feng J; Jin Y; Sun J; Geng R; Wei Y
    Cell Physiol Biochem; 2018; 47(2):641-653. PubMed ID: 29794468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma.
    Tai WT; Shiau CW; Chen PJ; Chu PY; Huang HP; Liu CY; Huang JW; Chen KF
    Hepatology; 2014 Jan; 59(1):190-201. PubMed ID: 23908138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nobiletin inhibits epithelial-mesenchymal transition of human non-small cell lung cancer cells by antagonizing the TGF-β1/Smad3 signaling pathway.
    Da C; Liu Y; Zhan Y; Liu K; Wang R
    Oncol Rep; 2016 May; 35(5):2767-74. PubMed ID: 26986176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
    Tai WT; Cheng AL; Shiau CW; Liu CY; Ko CH; Lin MW; Chen PJ; Chen KF
    Mol Cancer Ther; 2012 Feb; 11(2):452-63. PubMed ID: 22180308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.